Amylyx Pharmaceuticals, Inc. Stock Analysis & AI Score
Amylyx Pharmaceuticals, Inc. (AMLX) has an ST Score of 58.4 (B-), driven by its Valuation (A-) and held back by its Growth (C-). Analysts rate it Buy with a $52.20 price target (+73.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Amylyx Pharmaceuticals, Inc. (AMLX) has an ST Score of 58.4 (B-), driven by its Valuation (A-) and held back by its Growth (C-). Analysts rate it Buy with a $52.20 price target (+73.2% upside).
- Strongest
- ValuationA-
- Weakest
- GrowthC-
All factor grades
- ValuationA-
- Financial StrengthA-
- MomentumA-
- ForecastB+
- ProfitabilityC-
- GrowthC-
- Piotroski3/9
Contact
AMLX stock: frequently asked questions
What is AMLX's ST Score?
Amylyx Pharmaceuticals, Inc. (AMLX) has an ST Score of 58.4 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AMLX a buy, hold, or sell?
Analysts rate AMLX a Buy, with a price target of $52.20 (+73.2% vs the current price). Our ST Score grades it B- (58.4/100). The ST Score is a data-driven signal, not a recommendation.
What are AMLX's factor grades?
Valuation A-, Profitability C-, Financial Strength A-, Momentum A-, Growth C-, Forecast B+.
What is AMLX's valuation grade?
Amylyx Pharmaceuticals, Inc. (AMLX) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AMLX's growth grade?
Amylyx Pharmaceuticals, Inc. (AMLX) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AMLX's profitability grade?
Amylyx Pharmaceuticals, Inc. (AMLX) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AMLX's financial strength grade?
Amylyx Pharmaceuticals, Inc. (AMLX) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AMLX?
The average analyst price target for Amylyx Pharmaceuticals, Inc. (AMLX) is $52.20 from 11 analysts, which is +73.2% versus the recent price of $30.14.
What is AMLX's Piotroski score?
Amylyx Pharmaceuticals, Inc. (AMLX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.